Please ensure Javascript is enabled for purposes of website accessibility

How This Company Is Taking on Amgen

By Todd Campbell - Mar 23, 2017 at 9:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medicines Company is developing a new drug that could give Amgen's Repatha a run for its money in lowering bad cholesterol levels.

The Medicines Company (MDCO) recently announced positive phase 2 trial data for its cholesterol lowering drug, inclisiran, and if inclisiran can duplicate those results in a larger phase 3 study, then it could end up challenging Amgen (AMGN 0.94%) for market share in treating patients with stubbornly high levels of bad cholesterol.

Improving upon care

Amgen has made big waves in the cardiovascular community by developing an entirely new way of battling bad cholesterol.

Scientists work together in a lab developing new medicines to lower cholesterol.

Image source: Getty Images.

Doctors usually prescribe changes to diet and statin therapy to rein in bad cholesterol levels, however, statins don't work for everyone, and they come up particularly short in severe hypercholesterolemia patients with genetic mutations that cause their high cholesterol.

In those patients, doctors are turning to Amgen's Repatha to help patients reach their cholesterol targets. Unlike statins, which target statin production in the liver, Repatha targets PCSK9 proteins that break-down bad cholesterol receptors in the liver. By inhibiting the ability of those proteins to bind to receptors, Repatha lets patients clear more bad cholesterol from their blood.

After trials showed that adding Repatha to statins can reduce bad cholesterol levels by about 63%, Amgen won an FDA green light to begin marketing the drug in 2015.

So far, Repatha's $14,000 annual price tag has crimped its use, but Amgen recently reported results from a large cardiovascular outcome study that shows Repatha reduces the risk of heart attack and stroke by 15% or more. Pricing remains a hurdle, but the new data may compel more doctors to prescribe it, and if so, then Repatha's sales could climb meaningfully higher than their annualized $232 million run rate exiting December.

A better drug?

The Medicines Company's inclisiran may someday give doctors and patients an even better PCSK9 targeting option.

While Repatha targets the PCSK9 protein in the bloodstream to prevent it from binding to and breaking down receptors in the liver, inclisiran uses RNA technology from its collaboration partner Alnylam (ALNY 0.82%) to interrupt PCSK9 synthesis. Because inclisiran targets PCSK9 at the source, it may provide similar efficacy to Repatha with fewer annual doses.

In phase 2 trials, patients receiving two doses of inclisiran saw a mean reduction in bad cholesterol of 52.6% at 180 days, and importantly, that reduction was essentially maintained over 270 days.

That's pretty impressive considering the reduction came from only a starter dose and a booster dose at day 90. For comparison, Repatha is dosed either every other week, or monthly, depending on the patient.

Since PCSK9 is a valid target, and inclisiran is delivering strong efficacy, with fewer doses, it poses a meaningful threat to Repatha, especially if fewer doses provides insurers with cost-savings.

Uncertainty remains

In addition to Repatha, Regeneron (REGN 0.84%) and Sanofi (SNY 5.95%) market Praluent, another PCSK9 inhibitor. Praluent works similarly to Repatha, so it could also lose out if inclisiran's phase 3 trial is a success.

Regeneron and Sanofi, however, are locked in a patent battle with Amgen, and so far, they're on the losing side. If appeals don't go their way, then they may have to yank Praluent off the market, or cut a profit-sharing agreement with Amgen.

In any event, it's going to be a while before we know for sure that inclisiran is a winner, and because it works differently than Repatha and Praluent, there's no lock on its phase 3 trials panning out. Trials should begin soon though, so investors should keep tabs on The Medicines Company's progress. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

The Medicines Company Stock Quote
The Medicines Company
MDCO
Sanofi Stock Quote
Sanofi
SNY
$53.42 (5.95%) $3.00
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$245.37 (0.94%) $2.28
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$612.49 (0.84%) $5.10
Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
ALNY
$147.50 (0.82%) $1.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.